• H. Hof
  • U. Freund
  • W. Harms


In den westlichen Industrieländern ist das Mammakarzinom die häufigste Tumorerkrankung der Frau, an der etwa jede Elfte erkrankt (Tab. 18.1).


  1. Albain KS, Barlow WE, Ravdin PM, et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707):2055–2063PubMedGoogle Scholar
  2. Anderson GL, Limacher M, Assaf AR, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712PubMedGoogle Scholar
  3. Antoniou A, Pharoah PDP, Narod S, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet; 72(5):1117–1130PubMedGoogle Scholar
  4. Arriagada R, Lê MG, Rochard F, Contesso G. (1996) Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J. Clin. Oncol 14(5):1558–1564Google Scholar
  5. Atkins HL, Horrigan WD (1961) Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy. AJR 85:865–869Google Scholar
  6. Bartelink H, Horiot J, Poortmans PM, et al. (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25(22):3259–3265PubMedGoogle Scholar
  7. Bartelink H, Horiot JC, Poortmanns P et al. (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 11;345(19):1378–1387PubMedGoogle Scholar
  8. Bäsler R (1994) Pathologie des Mammakarzinoms. In: Klinische Onkologie 94/95. Schweizerische Rundschau für Medizin, Praxis Verlag Hallwag, S 216–233Google Scholar
  9. Baum M (2001) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 69(3):Abstract 8Google Scholar
  10. Bayerl A, Frank D, Lenz A et al. (2001) Lokale Tumorkontrolle und kosmetisches Ergebnis nach brusterhaltender Operation und Strahlentherapie bis 56 Gy Gesamtdosis ohne Boost beim Mammakarzinom. Strahlenther Onkol 1:25–32Google Scholar
  11. Becker H, Chang-Claude J (1996) Estimating population-specific disease risks for a given family history with an application to breast cancer. Fenet Epidemiol 13:229–242Google Scholar
  12. Becker N, Junkermann H (2008) Betrachtungen aus epidemiologischer Sicht: Nutzen und Risiko des Mammografiescreenings. Dtsch Arztebl 105(8): 131–136Google Scholar
  13. Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin Heidelberg New York Tokio, S 366–370Google Scholar
  14. Beckham WA, Popescu CC, Patenaude VV, et al. (2007) Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys 69:918–924PubMedGoogle Scholar
  15. Bentzen SM, Agrawal RK, Aird EGA, et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107PubMedGoogle Scholar
  16. Bentzen SM, Agrawal RK, Aird EGA, et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9(4):331–341PubMedGoogle Scholar
  17. Beral V. (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427PubMedGoogle Scholar
  18. Blichert-Toft M, Nielsen M, Düring M, et al. (2008) Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 47(4):672–681PubMedGoogle Scholar
  19. Block G, Patterson B, Suber A (1992) Fruit, vegetables and cancer prevention: A review of the epidemiological evidence. Nutr Cancer 18:1–29PubMedGoogle Scholar
  20. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMedGoogle Scholar
  21. Boccardo F et al. (1999) LHRH-agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): Results of a meta-analysis of four trials. Proc ASCO, abstract 416Google Scholar
  22. Boccardo F et al. (2001) Sequential Tamoxifen and Aminoglutethimide versus Tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 19(22):4209–4215PubMedGoogle Scholar
  23. Bonneterre J, Buzdar A, Nabholtz JM, et al. (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247–2258PubMedGoogle Scholar
  24. Buttgereit U (1998) Lokalrezidivhäufigkeit des Mammacarcinoms bei brusterhaltender Operationstechnik und eingeschränktem Bestrahlungsvolumen. Inauguraldissertation der Medizin. Fakultät der Universität FreiburgGoogle Scholar
  25. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med.;348(17):1625–1638PubMedGoogle Scholar
  26. Citron ML, Berry DA, Cirrincione C, et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol 21(8):1431–1439Google Scholar
  27. Clark RM, Whelan T, Levine M et al. (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillar dissection for node-negative breast cancer: An update. J Natur Cancer Inst 88:1659–1664Google Scholar
  28. Clarke M, Collins R, Darby S, et al. (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMedGoogle Scholar
  29. Cobleigh MA, Vogel CL, Tripathy NJ et al. (1998) Efficacy and safety of Herceptin (Human Anti-HER-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc ASCO 17:97aGoogle Scholar
  30. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727Google Scholar
  31. Coombes RC, Kilburn LS, Snowdon CF, et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570PubMedGoogle Scholar
  32. Cuzick J, Stewart H, Rutquist L et al. (1994) Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. JCO 12:447–453Google Scholar
  33. Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J. Clin. Oncol 27(10):1615–1620Google Scholar
  34. Dunst J, Eiermann W, Rauschecker HF, Winzer K-J, Wörrmann B (2002) Das lokale Rezidiv beim Mammakarzinom. Der Onkologe 8:867–873Google Scholar
  35. Early Breast Cancer Trialists Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trails. New Engl J Med 333:1444–1455Google Scholar
  36. Eidtmann H, de Boer R, Bundred N, et al. (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21 (11):2188–2194PubMedGoogle Scholar
  37. Ejlertsen B (1999) Comparable Effect of Ovarian Ablation (OA) and CMF Chemotherapy in Premenopausal Hormone Receptor Positive Breast Cancer Patients (PRP).ASCO Annual Meeting. Abstract 248Google Scholar
  38. Emdin SO, Granstrand B, Ringberg A, et al. (2006) SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536–543PubMedGoogle Scholar
  39. Erren TC (2001) A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics Suppl. 5: S105–119Google Scholar
  40. Feyer P, Sautter-Bihl M, Budach W, et al. (2010) DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol 186(2):63–69PubMedGoogle Scholar
  41. Fischer B, Redmond C, Fisher ER, Caplan R and other contributing NSABP investigators (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicator of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B06. J Clin Oncol 6:1076–1087Google Scholar
  42. Fisher B, Anderson S, Redmond CK, et al. (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333(22):1456–1461PubMedGoogle Scholar
  43. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20(20):4141–4149PubMedGoogle Scholar
  44. Fisher B, Dignam J, Wolmark N et al. (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMedGoogle Scholar
  45. Fisher B, Dignam J, Wolmark N et al. (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 353:1993–2001PubMedGoogle Scholar
  46. Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. NEJM 347:567–575PubMedGoogle Scholar
  47. Fletcher GH (1972) Local results of irradiation in the primary management of localized breast cancer. Cancer 29:549–551Google Scholar
  48. Floyd SR, Taghian AG (2009) Post-mastectomy radiation in large node-negative breast tumors: does size really matter? Radiother Oncol. 2009;91(1):33–37PubMedGoogle Scholar
  49. Fowble B, Hanlon A, Freedmann G et al. (2000) Internal mammary node irradiation either decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys 47:883–894PubMedGoogle Scholar
  50. Gerber B (2001) Einfluss von Umwelt, Ernährung und Lebensstil auf das Brustkrebsrisiko Dtsch Arztebl 98(24): A1612–1619Google Scholar
  51. Gnant M, Mlineritsch B, Schippinger W, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med 360(7):679–691PubMedGoogle Scholar
  52. Gold HT, Do HT, Dick AW (2008) Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancer. Cancer 113(11):3108–3115PubMedGoogle Scholar
  53. Goldhirsch A, Ingle JN, Gelber RD, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann. Oncol;20(8):1319–1329PubMedGoogle Scholar
  54. Goss PE, Ingle JN, Martino S, et al. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst 97(17):1262–1271PubMedGoogle Scholar
  55. Haffty B, Buchholz T, Perez C (2008) Breast Tumors: Early Stage Breast Cancer. In: Perez CA, Brady LW (Hrsg) Principles and practice of radiation oncology. 5. Auflage Lippincott, Philadelphia, pp 1175–1291Google Scholar
  56. Hammer J, Seewald DH, Track C et al. (1994) Breast cancer: primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation. Radiology 193:573–577PubMedGoogle Scholar
  57. Hammer J, Track C, Seewald DH, Spiegl K, Feichtinger J, Weis E (2002) 192-Ir HDR brachytherapy or electron beam boost or no boost in breast conserving therapy: a retrospective comparison. Strahlenther Oncol 178 (Sondernr. 1):3Google Scholar
  58. Harbeck N, Schmitt M, Meisner C, et al. (2009) Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. J Clin Oncol (Meeting Abstracts) 27(15S):511Google Scholar
  59. Harms W, Krempien R, Grehn C, Hensley F, Berns C, Wannemacher M (2003) Rebestrahlung der Thoraxwand bei lokal rezidivierenden Mammakarzinomen. Zentralbl GynäkolGoogle Scholar
  60. Harms W, Krempien R, Hensley F, Berns C, Fritz P, Wannenmacher M (2002) 5-year results of pulsed dose rate brachytherapy applied as a boost after breast-conserving therapy in patients at high risk for local recurrence from breast cancer. Strahlenther Oncol 11:607–614Google Scholar
  61. Hennequin C, Durdux C, Espie M et al. (1999) High-dose-rate brachytherapy for early breast cancer: an ambulatory technique. Int J Radiat Oncol Biol Phys 45:85–90PubMedGoogle Scholar
  62. Hoeller U, Borgmann K, Feyer P, Souchon R. (2007) On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer. Strahlenther Onkol 183(10):535–544PubMedGoogle Scholar
  63. Höffken K (2002) Neue TNM-Klassifikation bei Brustkrebs. Onkologe 8:789Google Scholar
  64. Hofmann W, Schlag PM, Scherneck S (1998) Genetische Prädisposition beim Mammacarcinom. Onkologe 4:868–877Google Scholar
  65. Holland et al. (1985) Histologic multifocality of Tis, T1-2 breast carcinoma. Implications for clinical trials of breast-conserving surgery. Cancer 56 (5):979–990Google Scholar
  66. Holli K, Hietanen P, Saaristo R, et al. (2009) Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J. Clin. Oncol. 2009 27(6):927–932PubMedGoogle Scholar
  67. Honrado E, Osorio A, Palacios J, Benitez J. (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene;25(43):5837–5845PubMedGoogle Scholar
  68. Honrado E, Osorio A, Palacios J, Benitez J. (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25(43):5837–5845PubMedGoogle Scholar
  69. Houghton J, George WD, Cuzick J, et al. (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 62(9378):95–102Google Scholar
  70. Howell A, Cuzick J, Baum M, et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62PubMedGoogle Scholar
  71. Jacobs H (1988) Experiences with interstitial HDR afterloading therapy in genital and breast cancer. Sonderb Strahlenther Onkol 82:266–270Google Scholar
  72. Jakesz R, Hausmaninger H, Kubista E, et al. (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 20(24):4621–4627PubMedGoogle Scholar
  73. Jakesz R, Jonat W, Gnant M, et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462PubMedGoogle Scholar
  74. Jatoi I, Proschan MA (2005) Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am. J. Clin. Oncol. 28(3):289–294Google Scholar
  75. Jones HA, Antonini N, Hart AAM, et al. (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J. Clin. Oncol. 27(30):4939–4947PubMedGoogle Scholar
  76. Julien JP, Bijker N, Fentiman IS et al. (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. Lancet 355:528–533PubMedGoogle Scholar
  77. Kaufmann M, Jonat W, v. Minckwitz G (2001) Aktuelle Empfehlung zur Therapie primärer Mammakarzinome. Dt Ärzteblatt 33:1839–1841Google Scholar
  78. Kohno N. (2008) Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int. J. Clin. Oncol. 13(1):18–23Google Scholar
  79. Konecny G, Pauletti G, Pegram M, et al. (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst 95(2):142–153Google Scholar
  80. Kreienberg R (2002) Mammakarzinom-Statements. Forum 1/02:36–41Google Scholar
  81. Kuhl C. (2007) The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 244(2):356–378PubMedGoogle Scholar
  82. Kurtz J (2001) Which patients don’t need a tumor-bed boost after whole-breast radiotherapy? Strahlenther Onkol 177:33–36PubMedGoogle Scholar
  83. Lancaster JM, Wooster R, Manjion J et al. (1996) BRCA2 mutations in primary breast and ovarian cancers. Nab Genet 13/2:238–240Google Scholar
  84. Lee SA, Ross RK, Pike MC. (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer. 92(11):2049–2058PubMedGoogle Scholar
  85. Liljegren G, Holmberg L, Adami HO, et al. (1994) Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J. Natl. Cancer Inst. 86(9):717–722PubMedGoogle Scholar
  86. Lind PA et al. (2002) Technical factors associated with radiation pneumonitis after local +/– regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 52(1): 137–143PubMedGoogle Scholar
  87. Lohr F, Heggemann F, Papavassiliu T et al. (2009) Is cardiotoxicity still an issue after breast-conserving surgery and could it be reduced by multifield IMRT? Strahlenther OnkolGoogle Scholar
  88. Lohrisch C, Paltiel C, Gelmon K, et al. (2006) Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol 24(30):4888–4894Google Scholar
  89. Look MP, van Putten WLJ, Duffy MJ, et al. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94(2):116–128PubMedGoogle Scholar
  90. Loomis DP, Savitz DA, Ananth CV (1994) Breast cancer mortality among female electrical workers in the United States. J Natl Cancer Just 86/12:921–925Google Scholar
  91. Manning M, Arthur DW, Schmidt-Ullrich RK et al. (2000) Interstitial high-dose-rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiat Oncol Biol Phys 48:1301–1306PubMedGoogle Scholar
  92. Martin M, Pienkowski T, Mackey J, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352(22):2302–2313PubMedGoogle Scholar
  93. Martín M, Rodríguez-Lescure A, Ruiz A, et al. (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J. Natl. Cancer Inst. 100(11):805–814PubMedGoogle Scholar
  94. Matzinger O, Heimsoth I, Poortmans P, et al. (2010) Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol. 49(1):24–34PubMedGoogle Scholar
  95. Mauriac L, Keshaviah A, Debled M, et al. (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 18(5):859–867PubMedGoogle Scholar
  96. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. (2007) Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 68(4):1004–1009PubMedGoogle Scholar
  97. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26):2666–2676PubMedGoogle Scholar
  98. Müller RP (2002) Strahlentherapie des Mammakarzinoms. In: Kreienberg et al. (Hrsg) Management des Mammakarzinoms, 2. Aufl. Springer, Berlin Heidelberg New York Tokio, S 205–221Google Scholar
  99. National Cancer Institute (2013) Breast Cancertreatment (PDQ): Health professional version. Zugegriffen:06. April 2013
  100. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. (2006) Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J. Clin. Oncol. 24(15):2268–2275PubMedGoogle Scholar
  101. Olivotto IA, Lesperance ML, Truong PT, et al. (2009) Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J. Clin. Oncol. 27(1):16–23PubMedGoogle Scholar
  102. Overgaard M, Nielsen HM, Overgaard J. (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 82(3):247–53PubMedGoogle Scholar
  103. Petrova-Schumann K, Lukas P (2002) Kosmetische Ergebnisse der brusterhaltenden Therapie des Mammakarzinoms nach postoperativer homogener Photonenbestrahlung mit 56 Gy. Strahlenther Oncol 178 (Sondernr. 1):4Google Scholar
  104. Poggi MM, Danforth DN, Sciuto LC, et al. (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 98(4):697–702PubMedGoogle Scholar
  105. Polgár C, Fodor J, Major T, et al. (2007) Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma–5-year results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 69(3):694–702PubMedGoogle Scholar
  106. Poortmans PM, Collette L, Horiot J, et al. (2009) Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol. 90(1):80–85PubMedGoogle Scholar
  107. Ragaz J, Olivotto IA, Spinelli JJ, et al. (2005) Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J. Natl. Cancer Inst. 97(2):116–126PubMedGoogle Scholar
  108. Recht A, Gray R, Davidson NE et al. (1999) Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689–1700PubMedGoogle Scholar
  109. Reitsamer R, Sedlmayer F, Kopp M, et al. (2006) The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations. Int. J. Cancer. 118(11):2882–2887PubMedGoogle Scholar
  110. Reitsamer R, Sedlmayer F, Kopp M, et al. (2008) Concepts and techniques of intraoperative radiotherapy (IORT) for breast cancer. Breast Cancer. 15(1):40–46PubMedGoogle Scholar
  111. Romestaing P, Lehingue Y, Carrie C et al. (1997) Role of 10 Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial, Lion/France. J Clin Oncol 15:963–968PubMedGoogle Scholar
  112. Rosen PP, Groshen S, Sanjo PE, Kinne DW, Hellmann S (1989) A long-term follow-up study of survival in Stage I (T1 N0 M0) and Stage II (T1 N1 M0) breast carcinoma. J Clin Oncol 7:355–366PubMedGoogle Scholar
  113. Rowell NP (2009) Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review. Radiother Oncol. 91(1):23–32PubMedGoogle Scholar
  114. Roy I, Fortin A, Larochelle M (2001) The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 58(3):333–339PubMedGoogle Scholar
  115. Sack H, Thesen N (1996) Brustdrüse, In: Scherer E, Sack H (Hrsg) Strahlentherapie Radiologische Onkologie, Kap. 34. S 661–681Google Scholar
  116. Sanghani M, Balk EM, Cady B (2009) Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Cancer. 115(8):1613–1620PubMedGoogle Scholar
  117. Sartor CI, Peterson BL, Woolf S, et al. (2005) Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J. Clin. Oncol. 23(1):30–40PubMedGoogle Scholar
  118. Sauer R (2000) Adjuvante Radiotherapie nach brusterhaltender Operation des Mammakarzinoms. Diagnostik und Therapie des Mammakarzinoms, State of the art. Zuckschwerd, München Bern Wien San Francisco, S 225–233Google Scholar
  119. Sautter-Bihl M, Budach W, Dunst J, et al. (2007) DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy. Strahlenther Onkol. 2007;183(12):661–666PubMedGoogle Scholar
  120. Sautter-Bihl M, Hültenschmidt B, Melcher U, Ulmer U (2002) Radiotherapy of internal mammary lymph nodes in breast cancer. Strahlenther Oncol 1:18–24Google Scholar
  121. Sautter-Bihl M, Souchon R, Budach W, et al. (2008) DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol. 184(7):347–53PubMedGoogle Scholar
  122. Sayer HG, Claßen J, Budach W, Höffken K (2002) Therapie des metastasierten Mammakarzinoms. Onkologe 8:874–879Google Scholar
  123. Schreer J (1998) Früherkennung und Prognosefaktoren beim Mammakarzinom. Onkologe 10:902–913Google Scholar
  124. Shak S, Paton V, Bajamonde A et al. (1998) Addition of Herceptin (Humanized Anti HER2 Antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc, ASCO 17:98 aGoogle Scholar
  125. Sickles E (2000) Breast imaging: from 1965 to the present. Radiology 215:1–16PubMedGoogle Scholar
  126. Silverstein MJ, Lagios MD, Groshen S et al. (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267–2274PubMedGoogle Scholar
  127. Silverstein MJ, Lagios MD, Groshen S et al. (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. NEJM 340:1455–1461PubMedGoogle Scholar
  128. Silverstein MJ. T (2003) he University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 186(4):337–343Google Scholar
  129. Sinclair S, Swain SM. (2010) Primary systemic chemotherapy for inflammatory breast cancer. Cancer 116(11 Suppl):2821–2828PubMedGoogle Scholar
  130. Smith I, Procter M, Gelber RD, et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555):29–36PubMedGoogle Scholar
  131. Smith-Warner SA, Spiegelman D, Yaun SS, et al. (1998) Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA;279(7):535–540PubMedGoogle Scholar
  132. Souchon R, Wenz F, Sedlmayer F, et al. (2009) DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol. 185(7):417–424PubMedGoogle Scholar
  133. Straver ME, Meijnen P, van Tienhoven G, et al. (2010) Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J. Clin. Oncol 28(5):731–737Google Scholar
  134. Straver ME, Meijnen P, van Tienhoven G, et al. (2010) Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann. Surg. Oncol. 17(7):1854–1861Google Scholar
  135. Strom EA, Woodward WA, Katz A, et al. (2005) Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63(5):1508–1513PubMedGoogle Scholar
  136. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD (2003) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy–a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 15(6):345–352Google Scholar
  137. Tallet AV, Salem N, Moutardier V, et al. (2003) Radiotherapy and immediate two-stage breast reconstruction with a tissue expander and implant: complications and esthetic results. Int. J. Radiat. Oncol. Biol. Phys. 57(1):136–142PubMedGoogle Scholar
  138. Thilmann C, Zabel A, Kuhn S et al. (2002) Invers geplante intensitätsmodulierte Strahlenbehandlung bei einer Patientin mit rechtsseitigem Mammakarzinom und Trichterbrust. Strahlenther Onkol 11:637–643Google Scholar
  139. Tjan-Heijnen VC, Pepels MJ, de Boer M, et al. (2009) Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study. J Clin Oncol (Meeting Abstracts). 27(18S):CRA506Google Scholar
  140. Toledano A, Garaud P, Serin D, et al. (2006) Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int. J. Radiat. Oncol. Biol. Phys. 65(2):324–332PubMedGoogle Scholar
  141. Tran NV, Chang DW et al. (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108 (July):78–82PubMedGoogle Scholar
  142. Truong PT, Jones SO, Kader HA, et al. (2009) Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 73(2):357–364PubMedGoogle Scholar
  143. Unnithan J, Macklis R (2001) Contralateral breast cancer risk. Radiother Oncol 60:239–246PubMedGoogle Scholar
  144. Untch M, de Waal JC, Dimpfl T et al. (2003) Klinik der In-situ-Karzinome. Manual Mammakarzinome, Tumorzentrum München. Zuckschwerdt, MünchenGoogle Scholar
  145. Vaidya JS, Joseph DJ, Tobias JS, et al. (2010) Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376(9735):91–102PubMedGoogle Scholar
  146. van Dongen JA, Voogd AC, Fentiman IS, et al. (2009) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J. Natl. Cancer Inst. 92(14):1143–1150Google Scholar
  147. Van Dyngen JA, Bartelink H, Fentismann JS et al. (1992) Factors influencing local relapse and survival and results of salonge treatment after breast conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TMM stage and II breast cancer. Eur J Cancer 28A:801–805Google Scholar
  148. Veronesi U, Cascinelli N, Mariani L, et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 347(16):1227–1232PubMedGoogle Scholar
  149. Veronesi U, Marubini E, Mariani L, et al. (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 12(7):997–1003PubMedGoogle Scholar
  150. Veronesi U, Paganelli G, Viale G, et al. (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349(6):546–553PubMedGoogle Scholar
  151. Viani GA, Stefano EJ, Afonso SL, et al. (2007) Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol. 2:28PubMedGoogle Scholar
  152. Wahl AO, Rademaker A, Kiel KD, et al. (2008) Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(2):477–484PubMedGoogle Scholar
  153. Wazer DE, Lowther D, Boyle T et al. (2001) Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early stage breast cancer. Int J Radiat Oncol Biol Phys 50:107–111PubMedGoogle Scholar
  154. Wenz F, Welzel G, Blank E, et al. (2010) Intraoperative Radiotherapy as a Boost During Breast-Conserving Surgery Using Low-Kilovoltage X-Rays: The First 5 Years of Experience With a Novel Approach. Int J Radiat Oncol Biol Phys. 77Google Scholar
  155. Whelan TJ, Pignol J, Levine MN, et al. (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362(6):513–520PubMedGoogle Scholar
  156. Winzer K, Sauer R, Sauerbrei W, et al. (2004) Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 40 (7):998–1005PubMedGoogle Scholar
  157. Wong JS, Kaelin CM, Troyan SL, et al. (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 24(7):1031–10366PubMedGoogle Scholar
  158. Wong JS, O’Neill A, Recht A, Schnitt SJ, Connolly JL, Silver B, Harris JR (2000) The relationship between lymphatic vessel invasion, tumor size, and pathologic nodes status: can we predict who can avoid a third field in the absence of axillary dissection? Int J Radiat Oncol Biol Phys 48(1):133–137PubMedGoogle Scholar
  159. Zavagno G, De Salvo GL, Scalco G, et al. (2008) A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann. Surg. 247(2):207–213PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • H. Hof
    • 1
  • U. Freund
    • 2
  • W. Harms
    • 3
  1. 1.Strahlentherapie Rhein/PfalzNeustadtDeutschland
  2. 2.Radioonkologische KlinikKlinikum OffenburgOffenburgDeutschland
  3. 3.RadioonkologieSt. Clara SpitalBaselSchweiz

Personalised recommendations